Amgen’s Repatha Reduces First-Time Cardiovascular Events by 25% in Major Clinical Trial

Amgen’s cholesterol drug Repatha (evolocumab), a PCSK9 inhibitor, demonstrated a 25% reduction in the risk of first major adverse cardiovascular events (such as heart attack, stroke, or coronary death) in high-risk adults without prior heart attack or stroke, when used in addition to statins or other LDL cholesterol-lowering treatments1246.

This result comes from the large Phase 3 VESALIUS-CV trial, which followed over 12,000 high-risk patients for nearly five years24.

Repatha reduced the risk of first heart attack by 36% compared to placebo in the same trial24.

Patients on Repatha achieved a median LDL cholesterol level of 45 mg/dL versus 109 mg/dL in the placebo group24.

The findings were presented at the 2025 American Heart Association Scientific Sessions and published in the New England Journal of Medicine14.

Repatha is now the first and only PCSK9 inhibitor proved to significantly reduce cardiovascular events as both primary and secondary prevention124.

Sources:

1. https://www.aspconline.org/news/amgens-repatha-cuts-risk-of-first-major-adverse-cardiovascular-events-by-25

2. https://www.app.stocks.news/news/amgen-makes-cholesterol-drugs-sexy-after-landmark-clinical-trial-data-license-to-print-money

4. https://www.investing.com/news/company-news/amgens-repatha-cuts-risk-of-first-heart-attack-by-36-in-trial-93CH-4344314

6. https://www.prnewswire.com/news-releases/amgens-repatha-cuts-risk-of-first-major-adverse-cardiovascular-events-by-25-in-landmark-phase-3-vesalius-cv-trial-302609344.html